Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + DC-CIK cell immunotherapy + hyperthermia
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Regional
01
Overview
This therapeutic regimen is a novel combination therapy being evaluated by Capital Medical University for the treatment of advanced malignant mesothelioma. It consists of the anti-PD-1 monoclonal antibody pembrolizumab (Keytruda), autologous dendritic cell-cytokine induced killer (DC-CIK) cell immunotherapy, and regional hyperthermia. Pembrolizumab functions as a checkpoint inhibitor by blocking the Programmed Cell Death Protein 1 (PD-1) receptor on T-cells, thereby preventing its interaction with ligands PD-L1 and PD-L2 to restore anti-tumor immune activity. The DC-CIK component involves the ex vivo expansion and activation of a patient's own mononuclear cells into a heterogeneous population of immune effectors (including dendritic cells and T-cells) intended to provide direct cytotoxicity and stimulate broader immune responses. Hyperthermia, delivered via the Thermotron RF-8EX device, is used to physically stress tumor cells, potentially increasing their immunogenicity and enhancing the infiltration and efficacy of the immunotherapy components within the tumor microenvironment.
- Other names
- pembrolizumab + autologous DC-CIK cell immunotherapy + hyperthermiaAnti-PD-1 antibody + DC-CIK Immunotherapy + Thermotron RF-8EX
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + DC-CIK cell immunotherapy + hyperthermia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + DC-CIK cell immunotherapy + hyperthermia.